These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 24192014)

  • 21. Novel vaccination approaches against equine alphavirus encephalitides.
    Carossino M; Thiry E; de la Grandière A; Barrandeguy ME
    Vaccine; 2014 Jan; 32(3):311-9. PubMed ID: 24295803
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of computational and recombinant technologies for developing novel influenza vaccines.
    Wong TM; Ross TM
    Expert Rev Vaccines; 2016; 15(1):41-51. PubMed ID: 26595182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Developments of subunit and VLP vaccines against influenza A virus.
    Deng MP; Hu ZH; Wang HL; Deng F
    Virol Sin; 2012 Jun; 27(3):145-53. PubMed ID: 22684468
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Viral vector-based influenza vaccines.
    de Vries RD; Rimmelzwaan GF
    Hum Vaccin Immunother; 2016 Nov; 12(11):2881-2901. PubMed ID: 27455345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunization against influenza: comparison of various topical and parenteral regimens containing inactivated and/or live attenuated vaccines in healthy adults.
    Keitel WA; Cate TR; Nino D; Huggins LL; Six HR; Quarles JM; Couch RB
    J Infect Dis; 2001 Jan; 183(2):329-332. PubMed ID: 11110645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in the vaccination of the elderly against influenza: role of a high-dose vaccine.
    Sullivan SJ; Jacobson R; Poland GA
    Expert Rev Vaccines; 2010 Oct; 9(10):1127-33. PubMed ID: 20923264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses.
    Li S; Liu C; Klimov A; Subbarao K; Perdue ML; Mo D; Ji Y; Woods L; Hietala S; Bryant M
    J Infect Dis; 1999 May; 179(5):1132-8. PubMed ID: 10191214
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Virus-vectored influenza virus vaccines.
    Tripp RA; Tompkins SM
    Viruses; 2014 Aug; 6(8):3055-79. PubMed ID: 25105278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age.
    Baxter R; Patriarca PA; Ensor K; Izikson R; Goldenthal KL; Cox MM
    Vaccine; 2011 Mar; 29(12):2272-8. PubMed ID: 21277410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Developing vaccines against pandemic influenza.
    Wood JM
    Philos Trans R Soc Lond B Biol Sci; 2001 Dec; 356(1416):1953-60. PubMed ID: 11779397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Live bivalent vaccine for parainfluenza and influenza virus infections.
    Maeda Y; Hatta M; Takada A; Watanabe T; Goto H; Neumann G; Kawaoka Y
    J Virol; 2005 Jun; 79(11):6674-9. PubMed ID: 15890905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bringing influenza vaccines into the 21st century.
    Settembre EC; Dormitzer PR; Rappuoli R
    Hum Vaccin Immunother; 2014; 10(3):600-4. PubMed ID: 24378716
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pandemic H5N1 influenza vaccine development: an update.
    El Sahly HM; Keitel WA
    Expert Rev Vaccines; 2008 Mar; 7(2):241-7. PubMed ID: 18324892
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The seasonal influenza vaccine Agriflu(®).
    Vajo Z
    Expert Rev Vaccines; 2011 Nov; 10(11):1513-7. PubMed ID: 22043951
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Use of a microfiltration method in producing inactivated influenza vaccine].
    Ivanov NB; Zhemkov VP; Gromov VI; Cherkasov AN; Shashkov LA
    Vopr Virusol; 1986; 31(4):404-9. PubMed ID: 3765563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Advances and challenges in the development and production of effective plant-based influenza vaccines.
    Yusibov V; Kushnir N; Streatfield SJ
    Expert Rev Vaccines; 2015 Apr; 14(4):519-35. PubMed ID: 25487788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy of live attenuated and inactivated influenza vaccines in children as a function of time postvaccination.
    Ambrose CS; Wu X; Belshe RB
    Pediatr Infect Dis J; 2010 Sep; 29(9):806-11. PubMed ID: 20458256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative efficacy of inactivated and live attenuated influenza vaccines.
    Monto AS; Ohmit SE; Petrie JG; Johnson E; Truscon R; Teich E; Rotthoff J; Boulton M; Victor JC
    N Engl J Med; 2009 Sep; 361(13):1260-7. PubMed ID: 19776407
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effectiveness and safety of influenza vaccination in children: European perspective.
    Heikkinen T; Heinonen S
    Vaccine; 2011 Oct; 29(43):7529-34. PubMed ID: 21820481
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccines in the prevention of viral pneumonia.
    Betts RF
    Semin Respir Infect; 1995 Dec; 10(4):282-7. PubMed ID: 8668856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.